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Aims: The effect of inhaled hypertonic saline (HS) on mucus-ciliar clearance in
Cystic Fibrosis (CF) patients is well known. Several studies evaluated its efﬁcacy
on lung function and number of exacerbations. In our study we evaluated if its use
may have any positive effect on nutritional status in CF patients.
Methods and Patients: In CF patients receiving HS 7% (5ml twice/day) for at
least 18 months, a retrospective evaluation of FVC, FEV1 and BMI pre- and during
treatment period (T0, and every 6 mo) was performed. 14 CF patients (8 males) aged
7−25 ys (mean age 17 y2mo) who received HS for 18−36 months consecutively
(mean duration of treatment 32mo) entered the study. Chronic Pseudomonas
aeruginosa infection was present in 9 patients, 1 also presented ABPA, 3 patients
have CFRD. Four out of 14 received nutritional supplementation (1 enteral, 3 oral)
during the study period.
Results: At starting HS only 2/14 patients had a FEV1 lower than 70% predicted.
During treatment FEV1 and FVC remained stable or showed a slight improvement
in 11/14 patients. As regard nutritional status a good improvement was noted in
mean BMI: BMI equal to 17.84 at start, showed a progressive increasing to 19.45
after 36 months in the whole studied cases. The increase of mean BMI from 18.2
to 20 was observed in the patients (10) not receiving nutritional supplementation.
Conclusions: Long-term HS has a positive effect on nutritional status in adolescent
patients with mild-moderate CF lung disease. Evaluation of growth and nutritional
status in a larger number of patients receiving long-term HS is needed to conﬁrm
this preliminary observation.
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Introduction: Lung transplantation (LTx) is a widely accepted treatment for end
stage cystic ﬁbrosis (CF). The prevalence of secondary pulmonary hypertension
(PH) in CF patients is estimated with ultrasound to be 21−49%. But the gold
standard, heart catheterization, is used in few studies because of the invasive nature.
The existence of PH increases the perioperative risk. Therefore, we measured mean
pulmonary artery pressure by right heart catheterization, in CF patients screened
for LTx.
Methods and Materials: CF patients evaluated for LTx between 2001 and 2008
were included. We excluded patients with incomplete or conﬂicting data. Right
heart catheterization was performed according to our protocol. PH was deﬁned as
mean pulmonary artery pressure greater than 25mmHg at rest with a pulmonary
capillary wedge pressure of 15mmHg or less. The forced expiratory volume in one
second was determined at moment of catheterization.
Results: 73 CF patients were screened for LTx and 68 were included (of whom
93% accepted for LTx). Median age was 31 (range 16−57) years at moment of
screening. During the study period, 35 patients were transplanted (56%) after a
median waiting time of 10 months (range 0−49).
16 CF patients (24%) were diagnosed with PH by heart catheterization. No
signiﬁcant differences were observed between the groups with or without PH
regarding to age, gender and number of enlisted patients. Lung function was
signiﬁcantly lower in the group with PH (p = 0.003). No correlation between lung
function and mean pulmonary artery pressure was found (p = 0.09).
Conclusions: This study demonstrated a prevalence of 24% for pulmonary hyper-
tension in CF patients screened for LTx.
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Rationale: To identify risk factors and long-term outcomes associated with
bronchial artery embolization (BAE) for hemoptysis in adults with cystic ﬁbrosis.
Methods: Consecutive adult CF subjects who received BAE in Cochin Hospital
(Paris, France) were individually matched (1:4) for age, gender and FEV1 with CF
subjects who did not have BAE. Multivariate conditional logistic regression was
used to identify independent factors associated with BAE. Transplant-free survival
and decline in lung function were analyzed using Kaplan-Meier and mixed model
analyses, respectively. Cox proportional hazards model were used to examine impact
of hemoptysis requiring BAE on survival.
Results: From 1994 to 2008, 48 subjects had BAE (BAE+) and were matched with
183 subjects (BAE−). Multivariate analysis indicated that variables associated with
disease severity (number of IV antibiotic days/yr and long-term oxygen therapy)
and bronchial colonization (Aspergillus sp. or mycobacteria) were independent risk
factors for BAE. Although BAE+ patient had shorter transplant-free survival, BAE
was not an independent factor associated with shorter survival. No difference in
FEV1 and FVC decline were identiﬁed between both groups.
Conclusion: Aspergillus colonization or mycobacterial infection are risk factors for
BAE. Patients who required BAE had more severe pulmonary disease and shorter
survival that was unrelated to embolization. No effect of hemoptysis requiring BAE
was found on rate of decline in lung function.
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In the last decade, lung transplantation (LT) has become an “ordinary” option in
CF patients with severe impairment of lung function. The spirometry is the easiest
and less expensive functional test utilized to follow-up these patients after LT.
Objective: To analyze the trend of spirometry after LT.
Methods: In more than 12 years we evaluated 60 CF patients (34 M, age
25.8±7.5 yrs) who underwent double-lung transplantation for severe respiratory
failure. Forced expiratory volumes have been detected one month after LT, every
3 months during the ﬁrst year and every 6 months after the ﬁrst year. We analyzed
mainly the FEV1 in form of percent of predicted values.
Results: After LT, all but three patients showed a rising trend in FEV1 that reached a
peak after 16.3±11.5SD months (rarely this phase was longer than 30 months). The
mean increase in FEV1 was 37.8±17.8DS% (differences calculated from the values
observed at the ﬁrst spirometry after LT). During our observation 21 patients died
after a mean period of 53±38.8SD months. In all but ﬁve of the deceased patients, a
sudden reduction in FEV1 has been observed in the last 6 months. In alive patients,
we observed three different FEV1 trends after the peak: 22 patients remained stable
around the peak values; 12 patients had a descending trend with a rate of reduction
of −4.5±2.4%/yr; 5 patients showed a stable phase followed by a sudden reduction
(−39.8±10.5%) and a subsequent stabilization.
Conclusions: The spirometry is an useful tool that give important information on
the lung health after lung transplantation, however it is not able to predict the sudden
reduction in lung function that is observed in deceased patients.
